Armata Pharmaceuticals (ARMP) Price & Analysis

Compare

297 Followers

ARMP Stock Chart & Stats

$3.48

$0.11(5.39%)

At close: Jan 08 4:00 PM EST

$3.48

$0.11(5.39%)

Day’s Range― - ―

52-Week Range$0.90 - $16.34

Previous CloseN/A

Volume48.90K

Average Volume (3M)536.86K

Market Cap

$242.38M

Enterprise Value$270.88M

Total Cash (Recent Filing)$14.76M

Total Debt (Recent Filing)$177.68M

Price to Earnings (P/E)―

Beta0.63

Next Earnings

Mar 19, 2026

EPS Estimate

-0.19

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.74

Shares Outstanding36,229,843

10 Day Avg. Volume121,090

30 Day Avg. Volume536,864

Financial Highlights & Ratios

PEG Ratio0.05

Price to Book (P/B)-1.39

Price to Sales (P/S)12.93

P/FCF Ratio-1.70

Enterprise Value/Market Cap1.12

Enterprise Value/Revenue53.60

Enterprise Value/Gross Profit76.07

Enterprise Value/Ebitda-8.92

Forecast

1Y Price Target

$9.00

Price Target Upside158.62% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical EfficacyAP-SA02 showed a 100% clinical response rate in MRSA patients by the end of the study.

Clinical TrialsNew data strongly support advancement of AP-SA02 into a pivotal Phase 3 trial, which the company plans to initiate pending FDA review and feedback.

Operational MilestonesThe formal commission of its state-of-the-art cGMP phage manufacturing facility is viewed as a positive operational milestone.

Bears Say

Earnings PerformanceArmata announced 3Q25 financial results, posting EPS of ($0.74) compared to analyst estimate of ($0.42).

Financial ChargesThe lower than expected EPS was due to a non-cash charge related to its convertible loan.

Armata Pharmaceuticals News

Armata Pharmaceuticals reports Q3 EPS (74c) vs. (15c) last year

Reports Q3 revenue $1.2M vs. $3.0M last year. As of September 30, Armata held approximately $14.8M of unrestricted...

24d ago

ARMP

Armata Pharmaceuticals trading resumes

10:10 EST Armata Pharmaceuticals (ARMP) trading resumes Published first on TheFly – the ultimate source for real-time, market-moving...

26d ago

ARMP

Armata Pharmaceuticals trading halted, volatility trading pause

10:05 EST Armata Pharmaceuticals (ARMP) trading halted, volatility trading pause Published first on TheFly – the ultimate source...

26d ago

ARMP

Armata announces comissioning of cGMP manufacturing facility in Los Angeles

Armata Pharmaceuticals (ARMP) announced that its state-of-the-art current Good Manufacturing Practice, or cGMP, manufacturing facility in Los Angeles,...

26d ago

ARMP

Armata Pharmaceuticals Enters Capital Sales Agreement

Armata Pharmaceuticals ( ($ARMP) ) has shared an announcement. On December 1, 2025, Armata Pharmaceuticals entered into a...

4d ago

ARMP

Armata Pharmaceuticals: Strategic Advancements and Clinical Progress Drive Buy Rating

Joseph Pantginis, an analyst from H.C. Wainwright, reiterated the Buy rating on Armata Pharmaceuticals. The associated price target...

23d ago

ARMP

Armata Pharmaceuticals: Strategic Advancements and Operational Milestones Justify Buy Rating

Analyst Joseph Pantginis of H.C. Wainwright reiterated a Buy rating on Armata Pharmaceuticals, retaining the price target of...

26d ago

ARMP

ARMP Earnings Report this Week: Is It a Buy, Ahead of Earnings?

Armata Pharmaceuticals Inc (ARMP) is scheduled to report 3rd quarter earnings on 11/12/2025. Regarding Q3 estimates, Wall Street...

26d ago

ARMP

Here’s Why Armata Pharmaceuticals Stock (ARMP) Exploded 300% Today

Armata Pharmaceuticals ($ARMP) stock exploded nearly 300% on Wednesday after the biotech firm released encouraging mid-stage trial data...

1M ago

ARMP

Armata Pharmaceuticals Reports Positive Phase 2a Study Results

Armata Pharmaceuticals ( ($ARMP) ) has issued an update. On October 22, 2025, Armata Pharmaceuticals announced positive results...

1M ago

ARMP

Promising Efficacy of Armata Pharmaceuticals’ AP-SA02 in Phase 2a Study Boosts Buy Rating

Armata Pharmaceuticals, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Joseph Pantginis from...

1M ago

ARMP

Armata data support advancing AP-SA02 to Phase 3, says H.C. Wainwright

H.C. Wainwright reiterates a Buy rating and $9 price target on Armata Pharmaceuticals (ARMP) after the company shared...

1M ago

ARMP

Armata Pharmaceuticals up 19% after reporting results of diSArm study

Armata Pharmaceuticals (ARMP) shares jumped 67c, or 19%, to $4.17 after resuming trading. Published first on TheFly –...

1M ago

ARMP

Armata Pharmaceuticals trading resumes

11:30 EDT Armata Pharmaceuticals (ARMP) trading resumes Published first on TheFly – the ultimate source for real-time, market-moving...

1M ago

ARMP

ARMP FAQ

What was Armata Pharmaceuticals Inc’s price range in the past 12 months?

Armata Pharmaceuticals Inc lowest stock price was $0.90 and its highest was $16.34 in the past 12 months.

What is Armata Pharmaceuticals Inc’s market cap?

Armata Pharmaceuticals Inc’s market cap is $242.38M.

When is Armata Pharmaceuticals Inc’s upcoming earnings report date?

Armata Pharmaceuticals Inc’s upcoming earnings report date is Mar 19, 2026 which is in 103 days.

How were Armata Pharmaceuticals Inc’s earnings last quarter?

Armata Pharmaceuticals Inc released its earnings results on Nov 12, 2025. The company reported -$0.74 earnings per share for the quarter, missing the consensus estimate of -$0.42 by -$0.32.

Is Armata Pharmaceuticals Inc overvalued?

According to Wall Street analysts Armata Pharmaceuticals Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Armata Pharmaceuticals Inc pay dividends?

Armata Pharmaceuticals Inc does not currently pay dividends.

What is Armata Pharmaceuticals Inc’s EPS estimate?

Armata Pharmaceuticals Inc’s EPS estimate is -0.19.

How many shares outstanding does Armata Pharmaceuticals Inc have?

Armata Pharmaceuticals Inc has 36,229,843 shares outstanding.

What happened to Armata Pharmaceuticals Inc’s price movement after its last earnings report?

Armata Pharmaceuticals Inc reported an EPS of -$0.74 in its last earnings report, missing expectations of -$0.42. Following the earnings report the stock price went down -4.634%.

Which hedge fund is a major shareholder of Armata Pharmaceuticals Inc?

Currently, no hedge funds are holding shares in ARMP

Armata Pharmaceuticals Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

-8.88%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Armata Pharmaceuticals Inc

Armata Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative therapies for the treatment of bacterial infections. The company specializes in harnessing the power of bacteriophage technology, which utilizes viruses that specifically target and kill bacteria. Armata's core product offerings include its proprietary phage therapies designed to address antibiotic-resistant infections, with an emphasis on personalized medicine approaches to combat specific pathogens.

Armata Pharmaceuticals (ARMP) Earnings & Revenues

Historic Earnings Reports

ARMP Stock 12 Month Forecast

Average Price Target

$9.00

▲(158.62% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","5":"$5","10":"$10","2.5":"$2.5","7.5":"$7.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$9.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$9.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$9.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,2.5,5,7.5,10],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.77,6.941538461538461,7.113076923076923,7.2846153846153845,7.456153846153846,7.627692307692308,7.799230769230769,7.97076923076923,8.142307692307693,8.313846153846153,8.485384615384616,8.656923076923077,8.82846153846154,{"y":9,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.77,6.941538461538461,7.113076923076923,7.2846153846153845,7.456153846153846,7.627692307692308,7.799230769230769,7.97076923076923,8.142307692307693,8.313846153846153,8.485384615384616,8.656923076923077,8.82846153846154,{"y":9,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.77,6.941538461538461,7.113076923076923,7.2846153846153845,7.456153846153846,7.627692307692308,7.799230769230769,7.97076923076923,8.142307692307693,8.313846153846153,8.485384615384616,8.656923076923077,8.82846153846154,{"y":9,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.36,"date":1730419200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":2.2,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.85,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.98,"date":1740787200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.44,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.34,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.94,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.89,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.54,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.55,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.96,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.91,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.77,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >